Acrivon Therapeutics, Inc. Common Stock (ACRV) - Total Assets
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) holds total assets worth $145.30 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Acrivon Therapeutics, Inc. Common Stock net assets for net asset value and shareholders' equity analysis.
Acrivon Therapeutics, Inc. Common Stock - Total Assets Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Acrivon Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Acrivon Therapeutics, Inc. Common Stock's total assets of $145.30 Million consist of 92.4% current assets and 7.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Acrivon Therapeutics, Inc. Common Stock market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acrivon Therapeutics, Inc. Common Stock's current assets represent 92.4% of total assets in 2024, an increase from 78.7% in 2020.
- Cash Position: Cash and equivalents constituted 20.3% of total assets in 2024, down from 72.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Acrivon Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Acrivon Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
Acrivon Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.75 | 12.75 | 34.46 |
| Quick Ratio | 8.75 | 12.75 | 34.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $115.47 Million | $174.16 Million | $97.49 Million |
Acrivon Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Acrivon Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.41 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | 42.2% |
| Total Assets | $196.59 Million |
| Market Capitalization | $52.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Acrivon Therapeutics, Inc. Common Stock's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Acrivon Therapeutics, Inc. Common Stock's assets grew by 42.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total assets of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $196.59 Million | +42.18% |
| 2023-12-31 | $138.26 Million | -23.71% |
| 2022-12-31 | $181.23 Million | +70.03% |
| 2021-12-31 | $106.59 Million | +4778.12% |
| 2020-12-31 | $2.19 Million | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more